tetano
Editor, Senior Moderator
Poult Sci
. 2023 Mar 20;102(6):102662.
doi: 10.1016/j.psj.2023.102662. Online ahead of print.
Recombinant hemagglutinin protein and DNA-RNA-combined nucleic acid vaccines harbored by yeast elicit protective immunity against H9N2 avian influenza infection
Huixia Zhang[SUP] 1 [/SUP], Ruyu Xie[SUP] 1 [/SUP], Han Zhang[SUP] 1 [/SUP], Ruiqi Sun[SUP] 1 [/SUP], Shujun Li[SUP] 1 [/SUP], Chuandao Xia[SUP] 2 [/SUP], Zexing Li[SUP] 1 [/SUP], Lilin Zhang[SUP] 1 [/SUP], Yanyu Guo[SUP] 1 [/SUP], Jinhai Huang[SUP] 3 [/SUP]
Affiliations
Abstract
A safe, convenience, and effective vaccine for controlling avian influenza virus infection is crucial in scale poultry production. Yeasts are considered useful vaccine vehicles for the delivery of antigens, which has been used to protect human and animal health. We report here the development of H9N2 strain hemagglutinin (HA)-based recombinant protein vaccines (rH9HA) and DNA-RNA-combined vaccine (rH9-DNA-RNA) in Saccharomyces cerevisiae for the first time. The immunogenicity assay indicated that both rH9HA and rH9-DNA-RNA could induce robust production of serum IgG, mucosal sIgA, and cellular immune responses. The reshape and diversification of gut microbiota and an enriched Lactobacillus, Debaryomyces were observed after oral immunization with rH9HA or rH9-DNA-RNA yeast vaccine, which might contribute to modulate the intestinal mucosal immunity and antiviral process. Oral immunized birds with either rH9HA or rH9-DNA-RNA were effectively protected from H9N2 virus challenge. Our findings suggested that yeast-derived H9N2 HA-based recombinant protein vaccines and DNA-RNA-combined nucleic acid vaccines are feasible and efficacious, opening up a new avenue for rapid and cost-effective production of avian influenza vaccines to achieve good protection effect.
Keywords: H9N2; gut microbiota; hemagglutinin; mucosal immune; vaccine.
. 2023 Mar 20;102(6):102662.
doi: 10.1016/j.psj.2023.102662. Online ahead of print.
Recombinant hemagglutinin protein and DNA-RNA-combined nucleic acid vaccines harbored by yeast elicit protective immunity against H9N2 avian influenza infection
Huixia Zhang[SUP] 1 [/SUP], Ruyu Xie[SUP] 1 [/SUP], Han Zhang[SUP] 1 [/SUP], Ruiqi Sun[SUP] 1 [/SUP], Shujun Li[SUP] 1 [/SUP], Chuandao Xia[SUP] 2 [/SUP], Zexing Li[SUP] 1 [/SUP], Lilin Zhang[SUP] 1 [/SUP], Yanyu Guo[SUP] 1 [/SUP], Jinhai Huang[SUP] 3 [/SUP]
Affiliations
- PMID: 37043959
- DOI: 10.1016/j.psj.2023.102662
Abstract
A safe, convenience, and effective vaccine for controlling avian influenza virus infection is crucial in scale poultry production. Yeasts are considered useful vaccine vehicles for the delivery of antigens, which has been used to protect human and animal health. We report here the development of H9N2 strain hemagglutinin (HA)-based recombinant protein vaccines (rH9HA) and DNA-RNA-combined vaccine (rH9-DNA-RNA) in Saccharomyces cerevisiae for the first time. The immunogenicity assay indicated that both rH9HA and rH9-DNA-RNA could induce robust production of serum IgG, mucosal sIgA, and cellular immune responses. The reshape and diversification of gut microbiota and an enriched Lactobacillus, Debaryomyces were observed after oral immunization with rH9HA or rH9-DNA-RNA yeast vaccine, which might contribute to modulate the intestinal mucosal immunity and antiviral process. Oral immunized birds with either rH9HA or rH9-DNA-RNA were effectively protected from H9N2 virus challenge. Our findings suggested that yeast-derived H9N2 HA-based recombinant protein vaccines and DNA-RNA-combined nucleic acid vaccines are feasible and efficacious, opening up a new avenue for rapid and cost-effective production of avian influenza vaccines to achieve good protection effect.
Keywords: H9N2; gut microbiota; hemagglutinin; mucosal immune; vaccine.